Goldman Sachs Group Inc Intellia Therapeutics, Inc. Transaction History
Goldman Sachs Group Inc
- $555 Billion
- Q1 2024
A detailed history of Goldman Sachs Group Inc transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 1,067,460 shares of NTLA stock, worth $22.8 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
1,067,460
Previous 824,527
29.46%
Holding current value
$22.8 Million
Previous $25.1 Million
16.81%
% of portfolio
0.01%
Previous 0.0%
Shares
17 transactions
Others Institutions Holding NTLA
# of Institutions
312Shares Held
89.3MCall Options Held
686KPut Options Held
599K-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl11MShares$235 Million2.16% of portfolio
-
Black Rock Inc. New York, NY9.11MShares$195 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.09MShares$194 Million0.01% of portfolio
-
State Street Corp Boston, MA4.6MShares$98.3 Million0.01% of portfolio
-
Deep Track Capital, LP Greenwich, CT4.21MShares$90 Million3.83% of portfolio
About Intellia Therapeutics, Inc.
- Ticker NTLA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,011,800
- Market Cap $1.63B
- Description
- Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...